Washington, DC, United States
Washington, DC, United States

Time filter

Source Type

Patent
Vanda Pharmaceuticals | Date: 2016-12-14

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.


Patent
Vanda Pharmaceuticals | Date: 2017-01-20

The present invention relates to novel fatty acid esters of the reversible Iloperidone metabolite P-88-8991, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.


Patent
Vanda Pharmaceuticals | Date: 2016-12-16

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.


Methods for predicting whether iloperidone will be efficacious in treating a psychotic symptom in an individual, based on the individuals genotype at one or more single nucleotide polymorphism (SNP) loci are described, as are methods for treating an individual based on such prediction. The genotypes mentioned in the claims are the SNPs rs4528226 located in the NUDT9P1 gene on chromosome 10q23.3 and rs7837682 located in the LZTS1 gene on chromosome 8p21.3.


Patent
Vanda Pharmaceuticals | Date: 2016-08-19

Melatonin Agonist, MA-1, is administered at effective doses.


Patent
Vanda Pharmaceuticals | Date: 2016-05-25

The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.


Patent
Vanda Pharmaceuticals | Date: 2015-09-08

The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.


Patent
Vanda Pharmaceuticals | Date: 2016-08-19

A method and composition for treating serotonin receptor-mediated conditions.


Patent
Vanda Pharmaceuticals | Date: 2016-03-30

The present invention relates to the prediction of antipsychotic treatment efficacy based on a patients genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.


Patent
Vanda Pharmaceuticals | Date: 2015-04-16

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Loading Vanda Pharmaceuticals collaborators
Loading Vanda Pharmaceuticals collaborators